Health spending represents one of the largest shares of overall public spending. The constant development of new medical technologies, ageing populations in several OECD countries and the need to respond to crises such as the COVID-19 are expected to further boost future medical spending. In this context, evaluating the cost effectiveness of health systems could contribute to better targeted spending.
Health cost effectiveness is assessed by comparing countries’ improvements in life expectancy (the most widely adopted and comparable outcome) to their total health expenditure per person. Life expectancy at birth can be affected by factors beyond health care activities and spending (e.g. living and working conditions, the physical environment, nutrition, and behavioural factors such as exercise, smoking and drug and alcohol consumption). Current expenditure encompasses both public and private spending; the latter is particularly high where people opt out from the system (e.g. Mexico) or where there are no comprehensive, public health schemes (e.g. the United States). Even so, there is a positive relationship between health spending and life expectancy. Some countries, such as Israel, Italy, Korea and Spain, have higher life expectancy than might be expected given their spending level. At the other end of the scale, Latvia, Lithuania and Mexico have comparatively low life expectancy for the amount they spend. Some of the factors explaining comparatively low life expectancy in Latvia and Lithuania are hazardous drinking, high exposure to air pollution and other risk factors for cardiovascular disease (OECD, 2019a). The United States also spends large amounts for the life expectancy it achieves. Privately provided health insurance in the United States tends to be expensive but other reasons such as high mortality rates from past smoking, high obesity rates and high death rates from opioid overdoses and road accidents help to explain its comparatively weak performance (Figure 13.13).